FDA Approves, Leqembi, New Treatment for Early Alzheimer’snews2023-01-06T22:58:48+00:00January 6th, 2023|The New York Times|
Abortion Pills Can Now Be Offered at Retail Pharmacies, F.D.A. Saysnews2023-01-04T03:19:55+00:00January 4th, 2023|The New York Times|
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogennews2022-12-29T19:54:35+00:00December 29th, 2022|The New York Times|
The F.D.A. Now Says It Plainly: Morning-After Pills Are Not Abortion Pillsnews2022-12-24T01:22:45+00:00December 24th, 2022|The New York Times|
Can a Federally Funded ‘Netflix Model’ Fix the Broken Market for Antibiotics?news2022-12-16T10:00:26+00:00December 16th, 2022|The New York Times|
FDA Approves a Drug That Can Delay Type 1 Diabetesnews2022-11-18T21:52:11+00:00November 18th, 2022|The New York Times|
FDA Panel Recommends Pulling Preterm Birth Drug From the Marketnews2022-10-19T19:50:02+00:00October 19th, 2022|The New York Times|
What A.L.S. and Alzheimer’s Drug Approvals Have in Commonnews2022-10-14T19:10:06+00:00October 14th, 2022|The New York Times|
F.D.A. Confirms Widespread Shortages of Adderallnews2022-10-13T18:04:42+00:00October 13th, 2022|The New York Times|
Price of New A.L.S. Treatment Will Be $158,000 Per Year, Maker Saysnews2022-09-30T20:16:18+00:00September 30th, 2022|The New York Times|
